The use of novel agents in multiple myeloma patients with hepatic impairment

Lindsay C. Stansfield, Wilson Gonsalves, Francis K. Buadi

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Novel drugs such as immunomodulators and proteasome inhibitors have improved the survival of patients with multiple myeloma. Like all therapeutic agents, appropriate dosing based on metabolism and clearance is important to maintain efficacy while avoiding toxicity. Hepatic impairment (HI) in multiple myeloma patients is rare but well described either due to disease or therapy-related factors. However, limited data are available on the appropriate use and dosing of the novel agent therapeutics in myeloma patients with HI. Furthermore, data on HI secondary to the novel agent toxicity are also sparse. This systematic review highlights the evidence on the use of novel agents like thalidomide, lenalidomide, pomalidomide, bortezomib and carfilzomib in patients with HI as well as their associated hepatic toxicities.

Original languageEnglish (US)
Pages (from-to)501-510
Number of pages10
JournalFuture Oncology
Volume11
Issue number3
DOIs
StatePublished - Jan 1 2015

Fingerprint

Multiple Myeloma
Liver
Proteasome Inhibitors
Thalidomide
Immunologic Factors
Therapeutics
Survival
Pharmaceutical Preparations

Keywords

  • hepatic impairment
  • myeloma
  • novel agents

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

The use of novel agents in multiple myeloma patients with hepatic impairment. / Stansfield, Lindsay C.; Gonsalves, Wilson; Buadi, Francis K.

In: Future Oncology, Vol. 11, No. 3, 01.01.2015, p. 501-510.

Research output: Contribution to journalReview article

Stansfield, Lindsay C. ; Gonsalves, Wilson ; Buadi, Francis K. / The use of novel agents in multiple myeloma patients with hepatic impairment. In: Future Oncology. 2015 ; Vol. 11, No. 3. pp. 501-510.
@article{90d25beaa5ba41dc869439af07063115,
title = "The use of novel agents in multiple myeloma patients with hepatic impairment",
abstract = "Novel drugs such as immunomodulators and proteasome inhibitors have improved the survival of patients with multiple myeloma. Like all therapeutic agents, appropriate dosing based on metabolism and clearance is important to maintain efficacy while avoiding toxicity. Hepatic impairment (HI) in multiple myeloma patients is rare but well described either due to disease or therapy-related factors. However, limited data are available on the appropriate use and dosing of the novel agent therapeutics in myeloma patients with HI. Furthermore, data on HI secondary to the novel agent toxicity are also sparse. This systematic review highlights the evidence on the use of novel agents like thalidomide, lenalidomide, pomalidomide, bortezomib and carfilzomib in patients with HI as well as their associated hepatic toxicities.",
keywords = "hepatic impairment, myeloma, novel agents",
author = "Stansfield, {Lindsay C.} and Wilson Gonsalves and Buadi, {Francis K.}",
year = "2015",
month = "1",
day = "1",
doi = "10.2217/fon.14.270",
language = "English (US)",
volume = "11",
pages = "501--510",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - The use of novel agents in multiple myeloma patients with hepatic impairment

AU - Stansfield, Lindsay C.

AU - Gonsalves, Wilson

AU - Buadi, Francis K.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Novel drugs such as immunomodulators and proteasome inhibitors have improved the survival of patients with multiple myeloma. Like all therapeutic agents, appropriate dosing based on metabolism and clearance is important to maintain efficacy while avoiding toxicity. Hepatic impairment (HI) in multiple myeloma patients is rare but well described either due to disease or therapy-related factors. However, limited data are available on the appropriate use and dosing of the novel agent therapeutics in myeloma patients with HI. Furthermore, data on HI secondary to the novel agent toxicity are also sparse. This systematic review highlights the evidence on the use of novel agents like thalidomide, lenalidomide, pomalidomide, bortezomib and carfilzomib in patients with HI as well as their associated hepatic toxicities.

AB - Novel drugs such as immunomodulators and proteasome inhibitors have improved the survival of patients with multiple myeloma. Like all therapeutic agents, appropriate dosing based on metabolism and clearance is important to maintain efficacy while avoiding toxicity. Hepatic impairment (HI) in multiple myeloma patients is rare but well described either due to disease or therapy-related factors. However, limited data are available on the appropriate use and dosing of the novel agent therapeutics in myeloma patients with HI. Furthermore, data on HI secondary to the novel agent toxicity are also sparse. This systematic review highlights the evidence on the use of novel agents like thalidomide, lenalidomide, pomalidomide, bortezomib and carfilzomib in patients with HI as well as their associated hepatic toxicities.

KW - hepatic impairment

KW - myeloma

KW - novel agents

UR - http://www.scopus.com/inward/record.url?scp=84923106242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923106242&partnerID=8YFLogxK

U2 - 10.2217/fon.14.270

DO - 10.2217/fon.14.270

M3 - Review article

C2 - 25675129

AN - SCOPUS:84923106242

VL - 11

SP - 501

EP - 510

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -